FindTrial
Sign In

TO KNOW ABOUT HOW THE IMMUNOHISTOCHEMICAL MARKERS PD-1 AND PD-L1 WILL EXPRESS IN BREAST CARCINOMA AND TO CORRELATE WITH IMMUNOTHERAPEUTIC INTERVENTION

TO STUDY EXPRESSION OF PD-1 AND PD-L1 IN BREAST CARCINOMA - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055103
Enrollment
70
Registered
2023-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Control Intervention1: NIL: NIL

Sponsors

Jawaharlal Nehru Medical College
Lead Sponsor
Shreya Ghosh
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All cases having a histopathological diagnosis of breast carcinoma and all modified radical mastectomy specimens.

Exclusion criteria

Exclusion criteria: Cases of adenomas, malignant lymphomas, myoepithelial lesions, nipple tumors, fibroepithelial tumors, and mesenchymal tumors, in male patients having breast carcinoma.

Design outcomes

Primary

MeasureTime frame
Incidence of expression of PD-1 and PD-L1 in breast carcinoma and its relation with prognosisTimepoint: Within 2 years—

Secondary

MeasureTime frame
To use it as a biomarker for planning immunotherapeutic intervention to improve the prognosis & to correlate with other clinicopathological individual parameters.Timepoint: Within 2 years—

Countries

India

Contacts

Public ContactDr Jayant S Makarande

Jawaharlal Nehru Medical College

drjayant_mak@rediffmail.com9960766675

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026